Rating Change
HC Wainwright & Co. analysts reiterated a Neutral rating on Evommune, Inc. (NYSE:EVMN) on August 03, 2026.
reiterateNYSE:EVMN
HC Wainwright & Co. Reiterates Neutral Rating on Evommune, Inc. (EVMN)
Rating Change HC Wainwright & Co. analysts reiterated a Neutral rating on Evommune, Inc. (NYSE:EVMN) on August 03, 2026.
Market Context
Evommune, Inc. operates in the Healthcare sector. The stock currently trades at $11.16 with a market capitalization of $261.7M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Evommune, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Evommune, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 03, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Jun 30, 2026 | Morgan Stanley | Overweight | N/A |
| Jun 30, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Jun 29, 2026 | William Blair | Market Perform | N/A |
| May 26, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View EVMN Stock Page
Frequently Asked Questions
What does a Neutral rating mean for EVMN?
A Neutral rating from HC Wainwright & Co. reflects the analyst's outlook on Evommune, Inc. (NYSE:EVMN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EVMN forecast page.